<p>It is a great honor to share the research success of the Krannert Cardiovascular Research Center (IU Krannert) at the Indiana University School of Medicine since we founded the center in 2021! Three years ago, we set out to expand the understanding of cardiovascular disease so we may develop novel diagnostics and therapeutics to reduce incidents of heart disease and ultimately relegate heart disease as the leading cause of death. I am happy to share that our investigators have expanded that knowledge, with new diagnostic tools and information, that will help shape and influence cardiovascular clinical care in the years ahead.</p>
<p>As the inaugural executive director of IU Krannert, it has been a privilege to carry on the legacy of more than 70 years of research performed by the Krannert Institute of Cardiology, in which Herman and Ellnora Krannert made possible.</p>
<p>In 2021, since our arrival, we ushered in a new era of a technology-driven research enterprise, where engineering, advanced imaging, omics and artificial intelligence play<br />
a significant role in the basic, translational and clinical cardiovascular research. We added more than 30 faculty members across multiple disciplines, including cardioinformatics, cardiopulmonary research, equity research, electrophysiology, ischemic heart disease, microcirculation and myocardial regenerative biology, where synergistic collaboration is paramount to success.</p>
<p>By 2023, we increased National Institutes of Health research funding from $1.1 million annually to more than $22 million annually. We also produced more than 225<br />
peer-reviewed publications, with 44 papers in high-impact academic journals. In this short period, IU Krannert also achieved these significant milestones: </p>
<ul>
<li>Revamped the cardiovascular clinical trials research program </li>
<li>Hosted the two-day Krannert Biennial, which brought to Indianapolis renowned cardiovascular researchers from around the world </li>
<li>Launched the first-in-human FDA-approved investigative clinical trial targeting ST Elevation Myocardial Infarction </li>
<li>Introduced the world's first classification of heart attacks based on tissue damage, which has been adopted by the Canadian Cardiovascular Society. </li>
</ul>
<div>Much of our success is due to the dedication of our investigative team, students and staff, who aspire to advance cardiovascular research and clinical care to benefit the next generation, as well as the many partners and collaborators we have located worldwide. </div>
<div></div>
<div>I invite you to explore the following pages to learn more about the innovative cardiovascular research happening here at IU School of Medicine. Our interdisciplinary team of investigators strive to develop and test novel diagnostics, pharmacological therapeutics and device-based interventions, which may one day bring transformative change in the management of cardiovascular care. </div>
<p> </p>
<div></div>
<div>Sincerely,</div>
<div></div>
<div></div>
<div> </div>
<p> </p>
<p> </p>
<div><strong>Rohan Dharmakumar, PhD</strong></div>
<div>Executive Director, Krannert Cardiovascular Research Center</div>
<div>Charles Fisch Professor of Cardiology</div>
<div>Director of Cardiovascular Imaging Research, Indiana Institute for Biomedical Imaging Sciences </div>
<p> </p>
3-Year Impact Report: Message from Executive Director
Feb 10, 2025
Rohan Dharmakumar, PhD, executive director of the Krannert Cardiovascular Research Center, IU School of Medicine
It is a great honor to share the research success of the Krannert Cardiovascular Research Center (IU Krannert) at the Indiana University School of Medicine since we founded the center in 2021! Three years ago, we set out to expand the understanding of cardiovascular disease so we may develop novel diagnostics and therapeutics to reduce incidents of heart disease and ultimately relegate heart disease as the leading cause of death. I am happy to share that our investigators have expanded that knowledge, with new diagnostic tools and information, that will help shape and influence cardiovascular clinical care in the years
ahead.
As the inaugural executive director of IU Krannert, it has been a privilege to carry on the legacy of more than 70 years of research performed by the Krannert Institute of Cardiology, in which Herman and Ellnora Krannert made possible.
In 2021, since our arrival, we ushered in a new era of a technology-driven research enterprise, where engineering, advanced imaging, omics and artificial intelligence play a significant role in the basic, translational and clinical cardiovascular research. We added more than 30 faculty members across multiple disciplines, including cardioinformatics, cardiopulmonary research, equity research, electrophysiology, ischemic heart disease, microcirculation and myocardial regenerative biology, where synergistic collaboration is paramount to success.
By 2023, we increased National Institutes of Health research funding from $1.1 million annually to more than $22 million annually. We also produced more than 225 peer-reviewed publications, with 44 papers in high-impact academic journals.
In this short period, IU Krannert also achieved these significant milestones:
Revamped the cardiovascular clinical trials research program
Hosted the two-day Krannert Biennial, which brought to Indianapolis renowned cardiovascular researchers from around the world
Launched the first-in-human FDA-approved investigative clinical trial targeting ST Elevation Myocardial Infarction
Introduced the world's first classification of heart attacks based on tissue damage, which has been adopted by the Canadian Cardiovascular Society
Much of the success is due to the dedication of our investigative team, students and staff, who aspire to advance cardiovascular research and clinical care to benefit the next generation, as well as the many partners and collaborators we have located worldwide.
I invited you to explore our achievements to learn more about the innovative cardiovascular research happening here at IU School of Medicine. Our interdisciplinary team of investigators strive to develop and test novel diagnostics, pharmacological therapeutics and device-based interventions, which may one day bring transformative change in the management of cardiovascular care.
Sincerely,
Rohan Dharmakumar, PhD
Executive Director, Krannert Cardiovascular Research Center
Charles Fisch Professor of Cardiology
Director for Cardiovascular Imaging Research, Indiana Institute for Biomedical Imaging Sciences
Rohan Dharmakumar, PhD